LV14345A - 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai - Google Patents

4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai

Info

Publication number
LV14345A
LV14345A LVP-09-181A LV090181A LV14345A LV 14345 A LV14345 A LV 14345A LV 090181 A LV090181 A LV 090181A LV 14345 A LV14345 A LV 14345A
Authority
LV
Latvia
Prior art keywords
ammonio
butanoate
dimethyl
ethyl
treatment
Prior art date
Application number
LVP-09-181A
Other languages
English (en)
Other versions
LV14345B (lv
Inventor
Ivars KALVIŅŠ
Maija Dambrova
Edgars LIEPIŅŠ
Original Assignee
Grindeks, A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grindeks, A/S filed Critical Grindeks, A/S
Priority to LVP-09-181A priority Critical patent/LV14345B/lv
Priority to KR1020127010343A priority patent/KR101355417B1/ko
Priority to ES10773886.6T priority patent/ES2508117T3/es
Priority to UAA201204970A priority patent/UA107201C2/ru
Priority to EP10773886.6A priority patent/EP2491005B1/en
Priority to SI201030752T priority patent/SI2491005T1/sl
Priority to GEAP201012677A priority patent/GEP20146123B/en
Priority to CN201080047660.5A priority patent/CN102666476B/zh
Priority to PT107738866T priority patent/PT2491005E/pt
Priority to EA201200514A priority patent/EA020303B1/ru
Priority to DK10773886.6T priority patent/DK2491005T3/da
Priority to PE2012000523A priority patent/PE20121473A1/es
Priority to MX2012004630A priority patent/MX2012004630A/es
Priority to RS20140547A priority patent/RS53620B1/en
Priority to ARP100103859A priority patent/AR081514A1/es
Priority to US13/503,144 priority patent/US9278907B2/en
Priority to PCT/EP2010/065924 priority patent/WO2011048201A1/en
Priority to BR112012009162A priority patent/BR112012009162B8/pt
Priority to CA2781499A priority patent/CA2781499C/en
Priority to JP2012534709A priority patent/JP5552169B2/ja
Priority to AU2010309756A priority patent/AU2010309756B2/en
Priority to PL10773886T priority patent/PL2491005T3/pl
Priority to MEP-2014-131A priority patent/ME01917B/me
Priority to NZ599521A priority patent/NZ599521A/xx
Publication of LV14345A publication Critical patent/LV14345A/lv
Publication of LV14345B publication Critical patent/LV14345B/lv
Priority to TNP2012000174A priority patent/TN2012000174A1/en
Priority to IL219217A priority patent/IL219217A0/en
Priority to CL2012001010A priority patent/CL2012001010A1/es
Priority to ZA2012/02916A priority patent/ZA201202916B/en
Priority to CO12065428A priority patent/CO6531459A2/es
Priority to CUP2012000065A priority patent/CU20120065A7/es
Priority to HK12110547.3A priority patent/HK1169824A1/xx
Priority to HRP20140964AT priority patent/HRP20140964T1/hr
Priority to SM201400176T priority patent/SMT201400176B/xx
Priority to US15/007,543 priority patent/US9573882B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Izgudrojums attiecas uz jaunu savienojumu 4-[etil(dimetil)amonija]butanoātu un tā iegūšanas metodi, kā arī uz tā izmantošanu kardiovaskulāro slimību ārstēšanā.
LVP-09-181A 2009-10-22 2009-10-22 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai LV14345B (lv)

Priority Applications (34)

Application Number Priority Date Filing Date Title
LVP-09-181A LV14345B (lv) 2009-10-22 2009-10-22 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai
BR112012009162A BR112012009162B8 (pt) 2009-10-22 2010-10-22 composto 4-[etil(dimetil)amônio] butanoato, seu processo preparação e usos
CA2781499A CA2781499C (en) 2009-10-22 2010-10-22 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
UAA201204970A UA107201C2 (uk) 2009-10-22 2010-10-22 4-[етил(диметил)амоній]бутаноат та його застосування в лікуванні серцево-судинної хвороби
ES10773886.6T ES2508117T3 (es) 2009-10-22 2010-10-22 Uso del butanoato de 4-[etil(dimetil)amonio)] en el tratamiento de la enfermedad cardiovascular
SI201030752T SI2491005T1 (sl) 2009-10-22 2010-10-22 Uporaba 4-(etil(dimetil)amonio)butanoata pri zdravljenju bolezni srca in oĺ˝ilja
JP2012534709A JP5552169B2 (ja) 2009-10-22 2010-10-22 ４−［エチル（ジメチル）アンモニオ］ブタノアートの、心血管疾患の治療における利用方法
CN201080047660.5A CN102666476B (zh) 2009-10-22 2010-10-22 4-[乙基(二甲基)铵基]丁酸盐在心血管疾病治疗中的用途
PT107738866T PT2491005E (pt) 2009-10-22 2010-10-22 Utilização de butanoato de 4-[etil(dimetil)amónio] no tratamento de doenças cardiovasculares
EA201200514A EA020303B1 (ru) 2009-10-22 2010-10-22 Применение 4-[этил(диметил)аммонио]бутаноата для лечения сердечно-сосудистых заболеваний
DK10773886.6T DK2491005T3 (da) 2009-10-22 2010-10-22 Anvendelse af 4-[ethyl(dimethyl)ammonio]butanoat i behandlingen af cardiovaskulære sygdomme
PE2012000523A PE20121473A1 (es) 2009-10-22 2010-10-22 Uso de 4-[etil(dimetil)amonio]butanoato en el tratamiento de enfermedades cardiovasculares
MX2012004630A MX2012004630A (es) 2009-10-22 2010-10-22 Uso de 4[etil(dimetil)amonio]butanoato en el tratamiento de la enfermedad cardiovascular.
RS20140547A RS53620B1 (en) 2009-10-22 2010-10-22 USE OF 4- [ETHYL (DIMETHYL) AMONIO] BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE
ARP100103859A AR081514A1 (es) 2009-10-22 2010-10-22 El compuesto 4-[etil(dimetil)amonio]butanoato, el metodo para la preparacion del mismo y el uso en el tratamiento de la enfermedad cardiovascular
US13/503,144 US9278907B2 (en) 2009-10-22 2010-10-22 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
PCT/EP2010/065924 WO2011048201A1 (en) 2009-10-22 2010-10-22 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
KR1020127010343A KR101355417B1 (ko) 2009-10-22 2010-10-22 심혈관 질환의 치료에 4-〔에틸(디메틸)암모니오〕부타노에이트의 사용
EP10773886.6A EP2491005B1 (en) 2009-10-22 2010-10-22 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
GEAP201012677A GEP20146123B (en) 2009-10-22 2010-10-22 ) usage of 4-[ethyl (dimethyl) ammonio] butanoate in treatment of cardiovascular disease
AU2010309756A AU2010309756B2 (en) 2009-10-22 2010-10-22 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
PL10773886T PL2491005T3 (pl) 2009-10-22 2010-10-22 Zastosowanie 4-[etylo(dimetylo)amonio]butanianu do leczenia chorób układu krążenia
MEP-2014-131A ME01917B (me) 2009-10-22 2010-10-22 Upotreba 4-[etil(dimetil)amonio]butanoata u lečenju kardiovaskularne bolesti
NZ599521A NZ599521A (en) 2009-10-22 2010-10-22 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
TNP2012000174A TN2012000174A1 (en) 2009-10-22 2012-04-16 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
IL219217A IL219217A0 (en) 2009-10-22 2012-04-16 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
CL2012001010A CL2012001010A1 (es) 2009-10-22 2012-04-20 Compuesto 4-[etil(dimetil)amonio]butanoato; procesos de preparacion de este compuesto; y su uso en el tratamiento de enfermedades cardiovasculares.
ZA2012/02916A ZA201202916B (en) 2009-10-22 2012-04-20 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
CO12065428A CO6531459A2 (es) 2009-10-22 2012-04-20 Uso de 4-[etil(dimetil)amonio] butanoato en el tratamiento de enfermedades cardiovasculares
CUP2012000065A CU20120065A7 (es) 2009-10-22 2012-04-23 Derivado de 4-[etil(dimetil)amonio] butanoato para el tratamiento de enfermedades cardiovasculares y sus métodos de obtención
HK12110547.3A HK1169824A1 (en) 2009-10-22 2012-10-24 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease 4-[()]
HRP20140964AT HRP20140964T1 (hr) 2009-10-22 2014-10-07 Uporaba 4-[etil(dimetil)amonijevog]butanoata u lijeäśenju kardiovaskularnih bolesti
SM201400176T SMT201400176B (it) 2009-10-22 2014-11-21 [Etil(dimetil)ammonio]butanoato nel trattamento diuna malattia cardiovascolare
US15/007,543 US9573882B2 (en) 2009-10-22 2016-01-27 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-09-181A LV14345B (lv) 2009-10-22 2009-10-22 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai

Publications (2)

Publication Number Publication Date
LV14345A true LV14345A (lv) 2011-05-20
LV14345B LV14345B (lv) 2011-07-20

Family

ID=43530044

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-09-181A LV14345B (lv) 2009-10-22 2009-10-22 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai

Country Status (33)

Country Link
US (2) US9278907B2 (lv)
EP (1) EP2491005B1 (lv)
JP (1) JP5552169B2 (lv)
KR (1) KR101355417B1 (lv)
CN (1) CN102666476B (lv)
AR (1) AR081514A1 (lv)
AU (1) AU2010309756B2 (lv)
BR (1) BR112012009162B8 (lv)
CA (1) CA2781499C (lv)
CL (1) CL2012001010A1 (lv)
CO (1) CO6531459A2 (lv)
CU (1) CU20120065A7 (lv)
DK (1) DK2491005T3 (lv)
EA (1) EA020303B1 (lv)
ES (1) ES2508117T3 (lv)
GE (1) GEP20146123B (lv)
HK (1) HK1169824A1 (lv)
HR (1) HRP20140964T1 (lv)
IL (1) IL219217A0 (lv)
LV (1) LV14345B (lv)
ME (1) ME01917B (lv)
MX (1) MX2012004630A (lv)
NZ (1) NZ599521A (lv)
PE (1) PE20121473A1 (lv)
PL (1) PL2491005T3 (lv)
PT (1) PT2491005E (lv)
RS (1) RS53620B1 (lv)
SI (1) SI2491005T1 (lv)
SM (1) SMT201400176B (lv)
TN (1) TN2012000174A1 (lv)
UA (1) UA107201C2 (lv)
WO (1) WO2011048201A1 (lv)
ZA (1) ZA201202916B (lv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8565150B2 (en) * 2009-03-11 2013-10-22 At&T Mobility Ii Llc Architectural model for LTE (long term evolution) EPC (evolved packet core) deployment
US20140088125A1 (en) * 2011-04-27 2014-03-27 Jsc Grindeks Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
DE102012109911A1 (de) 2011-10-19 2013-04-25 Electronics And Telecommunications Research Institute Energy harvesting device using electromagnetic interference signal and sensor system including the same
JO3117B1 (ar) * 2012-12-20 2017-09-20 Grindeks Jsc استعمال 3- كربوكسي- ن-إيثيل- ن، ن- ثاني ميثيل بروبان-1– أمينيوم أو ملح منه مقبول صيدلانياً في معالجة تصلب الشرايين
JO3333B1 (ar) 2013-09-26 2019-03-13 Grindeks Jsc استعمال 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium أو ملح مقبول دوائيا منه للوقاية من السكري وعلاجه
CN107879944B (zh) * 2017-10-30 2020-05-22 杭州海尔希畜牧科技有限公司 一种制备丁基甜菜碱的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1238868A (lv) 1967-08-08 1971-07-14
SU997646A1 (ru) 1978-11-27 1983-02-23 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср Кормова добавка
IT1210935B (it) 1981-09-17 1989-09-29 Inst Orch Sinteza Akademi Nauk Composizione farmaceutica per il trattamento di malattie cardiovascolari.
IT1190280B (it) * 1986-04-24 1988-02-16 Sigma Tau Ind Farmaceuti Procedimento per la preparazione di gamma-butirrobetaina
US4933103A (en) * 1987-03-23 1990-06-12 Kao Corporation Bleaching composition
SU1680693A1 (ru) * 1987-03-25 1991-09-30 Институт Органического Синтеза Ан Латвсср Этил-3-(2,2-диметил-2-этилгидразиний)пропионат иодистый, про вл ющий антиаритмическую активность
JPH0291049A (ja) * 1988-09-21 1990-03-30 Lonza Ag ｒ―ブチロベタインの製造方法
JP3119430B2 (ja) * 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
LV11728B (en) 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
US5973026A (en) 1998-02-02 1999-10-26 Xerox Corporation Ink jet inks
JP2000239239A (ja) * 1999-02-22 2000-09-05 Kankyo Meneki Gijutsu Kenkyusho:Kk クロルメコート類縁化合物のハプテン化合物、抗体及び測定方法
CA2508094A1 (en) 2005-05-20 2006-11-20 Vivier Canada Inc. Composition for accelerating collagen synthesis
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
LV13705B (en) 2006-11-06 2008-07-20 Ivars Kalvins Process for producing high purity intermolecular salt of 3-carboxy-n,n,n-trimethyl-propane-1-amine hydroxide
JP4761265B2 (ja) 2007-10-17 2011-08-31 学校法人甲南学園 核酸合成を促進する化合物を含む組成物およびその利用、並びに当該化合物の製造方法
CN101538214A (zh) * 2009-04-24 2009-09-23 潍坊祥维斯化学品有限公司 生产γ-丁基甜菜碱及其盐酸盐的方法
CN103547562A (zh) * 2011-04-27 2014-01-29 格林代克斯联合股份公司 4-[(卤代烷基)(二甲基)铵基]丁酸盐及其在治疗心血管疾病中的用途

Also Published As

Publication number Publication date
DK2491005T3 (da) 2014-10-27
AR081514A1 (es) 2012-10-03
US20160137589A1 (en) 2016-05-19
WO2011048201A1 (en) 2011-04-28
EA201200514A1 (ru) 2012-09-28
SMT201400176B (it) 2015-01-15
PT2491005E (pt) 2014-10-29
CA2781499C (en) 2015-03-24
CU24114B1 (lv) 2015-08-27
BR112012009162B1 (pt) 2021-02-02
CO6531459A2 (es) 2012-09-28
ES2508117T3 (es) 2014-10-16
US20120220656A1 (en) 2012-08-30
HK1169824A1 (en) 2013-02-08
JP2013508342A (ja) 2013-03-07
BR112012009162A2 (pt) 2020-08-18
CN102666476A (zh) 2012-09-12
NZ599521A (en) 2013-11-29
BR112012009162B8 (pt) 2021-07-27
US9278907B2 (en) 2016-03-08
KR101355417B1 (ko) 2014-01-27
CA2781499A1 (en) 2011-04-28
CN102666476B (zh) 2014-07-09
PL2491005T3 (pl) 2015-03-31
CL2012001010A1 (es) 2012-08-31
AU2010309756A1 (en) 2012-05-17
MX2012004630A (es) 2013-07-29
PE20121473A1 (es) 2012-11-18
ME01917B (me) 2015-05-20
CU20120065A7 (es) 2012-06-29
LV14345B (lv) 2011-07-20
US9573882B2 (en) 2017-02-21
RS53620B1 (en) 2015-04-30
EA020303B1 (ru) 2014-10-30
GEP20146123B (en) 2014-07-25
AU2010309756B2 (en) 2013-10-17
IL219217A0 (en) 2012-06-28
EP2491005B1 (en) 2014-07-23
SI2491005T1 (sl) 2014-12-31
JP5552169B2 (ja) 2014-07-16
UA107201C2 (uk) 2014-12-10
TN2012000174A1 (en) 2013-12-12
ZA201202916B (en) 2013-05-29
EP2491005A1 (en) 2012-08-29
KR20120101634A (ko) 2012-09-14
HRP20140964T1 (hr) 2014-12-05

Similar Documents

Publication Publication Date Title
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
CR20210072A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
HK1168584A1 (zh) 種新的丹酚酸化合物 、其製備方法和用途
EP3715345A3 (en) Preparation of lfa-1 inhibitor and polymorph thereof
MX2011003473A (es) Composiciones para el cuidado bucal.
TN2009000318A1 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
EP2437602A4 (en) OPHTHALMIC FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
MY164731A (en) Compound
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2011100671A3 (en) Methods and compositions to improve mechanical resistance of teeth
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
LV14345A (lv) 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai
WO2011149261A3 (ko) 치간 청소구
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
EP2488507A4 (en) NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
AU2012248013B2 (en) Intermediate for synthesizing caspofungin and preparation method therefor
UA110626C2 (uk) Спосіб одержання пан-інгібіторів циклінзалежної кінази формули (i), а також проміжні продукти цього процесу одержання
WO2011027359A3 (en) Process for the preparation of 4 -hydroxy atomoxetine and intermediates in the manufacture thereof
WO2011156820A9 (en) Compositions, methods and uses for treatment of type 1 diabetes
UA98698C2 (en) Phenylsulfanylphenyl-piperidines and process for the preparation thereof
WO2010059916A3 (en) Preparation of docetaxel